Physician profile
Brian Bailey
NPI 1265430656
$3,539.71
in general payments reported to CMS, 2019-2025
26 companies · $625 in 2025
The $625 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $330 · 2021: $337 · 2022: $569 · 2023: $353 · 2024: $725 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $613.90 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $401.79 | 2022-2025 | Azstarys |
| Tris Pharma INC | $347.71 | 2019-2023 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $240.49 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $235.94 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $216.53 | 2019-2021 | |
| Neos Therapeutics, Lp | $193.71 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $180.41 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $153.23 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $146.32 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $139.27 | 2024-2025 | |
| Pfizer INC. | $130.70 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $80.59 | 2024-2025 | Zoryve |
| Acadia Pharmaceuticals INC | $79.15 | 2023-2025 | Daybue |
| Seqirus USA INC | $66.90 | 2022-2025 | Flucelvax, Fluad |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $58.41 | 2019 | |
| Collegium Pharmaceutical, INC. | $43.64 | 2025 | Jornay Pm |
| Sobi, INC | $37.77 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $36.31 | 2019-2020 | |
| Shire North American Group INC | $30.14 | 2019 | |
| Kaleo, INC. | $26.10 | 2020-2022 | |
| Biogen, INC. | $23.72 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $15.10 | 2024 | Flumist Quadrivalent |
| Aytu Biopharma, INC. | $14.61 | 2024 | Karbinal |
| Vertical Pharmaceuticals, LLC | $13.75 | 2025 | Relexxii |
| Amneal Pharmaceuticals LLC | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.